Impairment of the Ability of HDL From Patients With Metabolic Syndrome but Without Diabetes Mellitus to Activate eNOS: Correction by S1P Enrichment

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 37; no. 5; pp. 804 - 811
• Main Authors: Denimal, Damien, Monier, Serge, Brindisi, Marie-Claude, Petit, Jean-Michel, Bouillet, Benjamin, Nguyen, Amandine, Demizieux, Laurent, Simoneau, Isabelle, Pais de Barros, Jean-Paul, Vergès, Bruno, Duvillard, Laurence
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01.05.2017; American Heart Association
• Subjects: Adult; Aged; Cardiology and cardiovascular system; Case-Control Studies; Cells, Cultured; Diabetes Mellitus - blood; Diabetes Mellitus - diagnosis; Diabetes Mellitus - enzymology; Disease Progression; Enzyme Activation; Female; Hematology; Human health and pathology; Human Umbilical Vein Endothelial Cells - enzymology; Humans; Life Sciences; Lipoproteins, HDL - blood; Lysophospholipids - blood; Male; Metabolic Syndrome - blood; Metabolic Syndrome - diagnosis; Metabolic Syndrome - enzymology; Middle Aged; Nitric Oxide Synthase Type III - metabolism; Phosphorylation; Proto-Oncogene Proteins c-akt - metabolism; Sphingosine - analogs & derivatives; Sphingosine - blood; metabolic syndrome; HDL; eNOS; sphingosine

OBJECTIVE—High-density lipoprotein (HDL) from nondiabetic patients with metabolic syndrome (MetS) displays abnormalities in their lipidome, such as triglyceride enrichment and sphingosine-1-phosphate depletion. We hypothesized that these abnormalities could impair the ability of HDL to stimulate end...